{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:49:04Z","timestamp":1761896944731,"version":"3.40.5"},"reference-count":18,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T00:00:00Z","timestamp":1550620800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32HL007439\u201040"],"award-info":[{"award-number":["5T32HL007439\u201040"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hepatocellular carcinoma (HCC) is a challenging to treat malignancy with few available systemic therapies. Angiogenesis has been implicated in the pathogenesis of <jats:styled-content style=\"fixed-case\">HCC<\/jats:styled-content> and prior studies have suggested a role for anti\u2010<jats:styled-content style=\"fixed-case\">VEGF<\/jats:styled-content> therapy. Prior to <jats:styled-content style=\"fixed-case\">FDA<\/jats:styled-content> approval of second\u2010line therapy for advanced <jats:styled-content style=\"fixed-case\">HCC<\/jats:styled-content>, from 2008 until 2017, we initiated bevacizumab monotherapy (5\u201010\u00a0mg\/kg every 2\u20103\u00a0weeks) in 12 patients with intolerance of or progression during sorafenib therapy. Bevacizumab therapy was well tolerated with only 1\/12 patients experiencing a grade 3\u20104 treatment\u2010related adverse event (transient ischemic attack) and only 2\/12 patients discontinued the therapy due to adverse events. Median overall survival was 20.2\u00a0months (<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content>, 7.0\u201043.5), with a median time to radiologic progression of 10.4\u00a0months (<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content>, 2.8\u201016.1) and a disease control rate of 54%. Taken together, our experience provides rationale for further prospective investigation of bevacizumab for the treatment of advanced <jats:styled-content style=\"fixed-case\">HCC<\/jats:styled-content>.<\/jats:p>","DOI":"10.1002\/cam4.2015","type":"journal-article","created":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T05:21:54Z","timestamp":1550726514000},"page":"1442-1446","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Utility of bevacizumab in advanced hepatocellular carcinoma: A veterans affairs experience"],"prefix":"10.1002","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8120-1132","authenticated-orcid":false,"given":"Max M.","family":"Wattenberg","sequence":"first","affiliation":[{"name":"Division of Hematology\u2010Oncology Perelman School of Medicine University of Pennsylvania  Philadelphia PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nevena","family":"Damjanov","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2010Oncology Perelman School of Medicine University of Pennsylvania  Philadelphia PA, USA"},{"name":"Hematology\u2010Oncology Section Corporal Michael J. Crescenz VA Medical Center  Philadelphia PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David E.","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Perelman School of Medicine University of Pennsylvania  Philadelphia PA, USA"},{"name":"Gastroenterology Section Corporal Michael J. Crescenz VA Medical Center  Philadelphia PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,2,20]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"Cancer Stat Facts: Liver and Intrahepatic Bile Duct Cancer SEER: National Cancer Institute DCCPS Surveillance Research Program;2018https:\/\/seer.cancer.gov\/statfacts\/html\/livibd.html."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.20324"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i6.498"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.9947"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605580"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26556"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25889"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27304"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1247132"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3294-8"},{"key":"e_1_2_7_13_1","unstructured":"TherneauTM.A package for survival analysis in S. version 2.38.2015."},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32453-9"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30207-1"},{"key":"e_1_2_7_16_1","unstructured":"ZhuAX KangY\u2010K YenC\u2010J et\u00a0al.REACH\u20102: A randomized double\u2010blind placebo\u2010controlled phase 3 study of ramucirumab versus placebo as second\u2010line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha\u2010fetoprotein (AFP) following first\u2010line sorafenib. 2018 ASCO Annual Meeting \u2010 Oral Abstract Session.2018."},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1717002"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0051"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.2015","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.2015","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.2015","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.2015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T21:14:41Z","timestamp":1704230081000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.2015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,20]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1002\/cam4.2015"],"URL":"https:\/\/doi.org\/10.1002\/cam4.2015","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"type":"print","value":"2045-7634"},{"type":"electronic","value":"2045-7634"}],"subject":[],"published":{"date-parts":[[2019,2,20]]},"assertion":[{"value":"2018-11-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}